furmonertinib + anlotinib

Furmonertinib + anlotinib is an investigational oral combination therapy comprising two small molecule drugs: furmonertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), and anlotinib, a multi-targeted tyrosine kinase inhibitor with anti-angiogenic properties. The combination is being evaluated primarily as a first-line treatment for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring EGFR mutations, including EGFR exon 20 insertion mutations, and for those with brain metastases. Furmonertinib selectively inhibits mutant EGFR tyrosine kinase activity, while anlotinib inhibits multiple receptor tyrosine kinases involved in tumor angiogenesis and proliferation, including VEGFR, FGFR, PDGFR, and c-Kit. Clinical studies and case reports indicate that this combination may offer enhanced efficacy and disease control in NSCLC, particularly in populations with limited response to EGFR-TKI monotherapy[1][3][4][5][6][8].

Brand names

Elunate

Other names

furmonertinib and anlotinibfurmonertinib plus anlotinibfurmonertinib combined with anlotinib